|$23M||17 Jun 2021||Massachusetts, United States|
|$10M||09 Mar 2021||Oakland, California, United States|
|$9M||02 Feb 2021||California, United States|
|$7M||01 Feb 2021||South Korea, Gyeonggi-do, South Korea|
|$7M||03 Feb 2020||Chiyoda|
|$17M||24 Dec 2019||Chiyoda|
|$15M||01 Dec 2019||South Korea|
|$43M||15 Jan 2019||South Korea, Gyeonggi-do, South Korea|
|$11M||06 Jan 2019||South Korea|
– S-Alpha Therapeutics announced the completion of its Series A financing.
– The company raised a total of $8.7M USD (10 Billion KRW) in financing round.
– In Series A funding, all existing investors participated in this investment, and Korea Investment Partners, Stonebridge Ventures, Devsisters Ventures/KDB Capital, and Timewise Investment participated as new investors.
– OpenExchange, a Boston, MA-based provider of video and virtual event solutions for financial communications, completed an initial closing of nearly $23m in Series D funding.
– The round was led by Kingfisher Investment Advisors and Stonebridge Ventures.
– The company intends to use the funds for further development of its recently-announced OE VIZION, a next-generation platform for virtual and hybrid events, as well as complementary acquisitions in content development, meeting logistics, media streaming, and data analytics.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.